March 17, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Altamira Therapeutics Ltd. (the “Company”) | |
| Withdrawal of Request for Acceleration | ||
| Registration Statement on Form F-1 (File No. 333-269823) |
Ladies and Gentlemen:
On March 13, 2023, the Company requested acceleration of the effective date of the above-referenced Registration Statement so that it would become effective at 5:00PM on Wednesday, March 15, 2023 or as soon thereafter as practicable. We hereby withdraw such request.
| Very truly yours, | ||
| Altamira Therapeutics Ltd. | ||
| By: | /s/ Thomas Meyer | |
| Name: | Thomas Meyer | |
| Title: | Chief Executive Officer | |
